Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to characterize the medical management of squamous cell carcinoma head and neck (SCCHN) patients diagnosed with recurrent/metastatic (R/M) disease (between 01July2013 and 30 June 2014) in the real-world setting.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Population with R/M SCCHN | Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Best Therapy Response defined as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) based on physician's assessment for each therapy regimen | approximately 12 months | |
| Overall Survival(OS) of patients with an Index diagnosis of R/M SCCHN | approximately 12 months | |
| Progression-Free Survival(PFS) of patients with an Index diagnosis of R/M SCCHN | approximately 12 months | |
| Recurrent-Free Survival(RFS) of patients with an Index diagnosis of R/M SCCHN | approximately 12 months | |
| Overall Response Rate(ORR) of patients with an Index diagnosis of R/M SCCHN | approximately 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of R/M SCCHN-related health care resource use | approximately 12 months | |
| Treatment selection conditional on patient demographics, comorbidities, disease severity, and other characteristics as well as clinician demographics, therapy preferences, and other characteristics |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with R/M SCCHN between 01July2013 and 30June2014
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| approximately 12 months |
| Best Therapy Response conditional on patient demographics, comorbidities, disease severity, treatment received, and other characteristics | approximately 12 months |